{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:54:14Z","timestamp":1761177254182,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.diabet.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T11:54:56Z","timestamp":1438257296000},"page":"425-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice"],"prefix":"10.1016","volume":"41","author":[{"given":"K.","family":"Nonogaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2015.06.005_bib0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1126\/science.1072327","article-title":"Activation of central melanocortin pathways by fenfluramine","volume":"297","author":"Heisler","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.diabet.2015.06.005_bib0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00213-004-1864-0","article-title":"Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice","volume":"176","author":"Lee","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.diabet.2015.06.005_bib0075","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/en.2006-0418","article-title":"Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice","volume":"147","author":"Nonogaki","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2015.06.005_bib0080","first-page":"675","article-title":"Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors","volume":"5","author":"Nonogaki","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.diabet.2015.06.005_bib0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S1461145708009619","article-title":"Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene","volume":"12","author":"Nonogaki","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.diabet.2015.06.005_bib0090","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1017\/S1461145710000672","article-title":"Hypothalamic orexin and pro-opiomelanocortin activities are essential for the anorexic effects of m-chlorophenylpiperazine in mice","volume":"13","author":"Nonogaki","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.diabet.2015.06.005_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00210-008-0276-9","article-title":"Serotonin pharmacology in gastrointestinal tract: a review","volume":"377","author":"Beatie","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.diabet.2015.06.005_bib0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.15344\/2393-8498\/2014\/108","article-title":"5-HT4 Receptor agonists in the treatment of gastrointestinal motility disorders: current status and perspective","volume":"1","author":"Lee","year":"2014","journal-title":"Int J Gastroenterol Disord Ther"},{"key":"10.1016\/j.diabet.2015.06.005_bib0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2005","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2015.06.005_bib0110","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1177\/1060028013504076","article-title":"Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus","volume":"47","author":"Jarvis","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diabet.2015.06.005_bib0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1476-5381.2009.00145.x","article-title":"Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and \u03b2-cell function in db\/db mice","volume":"157","author":"Morita","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabet.2015.06.005_bib0120","doi-asserted-by":"crossref","first-page":"751930","DOI":"10.1155\/2014\/751930","article-title":"Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice","volume":"2014","author":"Nonogaki","year":"2014","journal-title":"Biomed Res Int"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363615000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363615000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:55:06Z","timestamp":1761130506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363615000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1262363615000919"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2015.06.005","relation":{},"ISSN":["1262-3636"],"issn-type":[{"type":"print","value":"1262-3636"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}